Dermatheory

About Dermatheory

Dermatheory, also known as Indomo Therapeutics, is a clinical-stage therapeutics company founded in 2021 by Jack Abraham and Rick Bente. The company is headquartered in San Francisco and is focused on developing device-enabled, at-home treatments for inflammatory skin conditions. The company's main product under development is the ClearPen™, a novel intradermal self-injection device designed to be used with their drug candidate, DT-001. This combination aims to provide a fast-acting, at-home solution for moderate to severe inflammatory acne lesions. The goal is to replicate the effects of intralesional triamcinolone acetonide injections, a treatment recommended by the American Academy of Dermatology, and shift this standard of care from a clinical setting into the patient's hands. By controlling the dosage, depth, and volume of the injection, the ClearPen™ is intended to empower patients to safely manage their condition at home. The products are currently investigational and have not been approved by the FDA. As a venture capital-backed company, Indomo has secured significant funding to support its clinical trials and product development. It raised $25 million in a Series B funding round on October 30, 2025, with investors including Foresite Capital, Polaris Partners, and Atomic. The company has a team with expertise in drug delivery, consumer health, telehealth, and medical devices.